Literature DB >> 19185842

T cell acute lymphoblastic leukemia: NOTCHing the way toward a better treatment outcome.

Ching-Hon Pui1.   

Abstract

Gamma-secretase inhibitors block the activation of NOTCH1 but have limited activity against T cell acute lymphoblastic leukemia (T-ALL) and cause severe gastrointestinal toxicity. In a recent study, Real et al. show that a potent gamma-secretase inhibitor potentiates the cytotoxicity of dexamethasone against glucocorticoid-resistant T-ALL cells, while dexamethasone abrogates the gastrointestinal toxicity induced by the gamma-secretase inhibitor.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19185842     DOI: 10.1016/j.ccr.2009.01.007

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  12 in total

1.  Inhibition of IRAK1/4 sensitizes T cell acute lymphoblastic leukemia to chemotherapies.

Authors:  Zhaoyang Li; Kenisha Younger; Ronald Gartenhaus; Ann Mary Joseph; Fang Hu; Maria R Baer; Patrick Brown; Eduardo Davila
Journal:  J Clin Invest       Date:  2015-02-02       Impact factor: 14.808

2.  IKKα activation of NOTCH links tumorigenesis via FOXA2 suppression.

Authors:  Mo Liu; Dung-Fang Lee; Chun-Te Chen; Chia-Jui Yen; Long-Yuan Li; Hong-Jen Lee; Chun-Ju Chang; Wei-Chao Chang; Jung-Mao Hsu; Hsu-Ping Kuo; Weiya Xia; Yongkun Wei; Pei-Chun Chiu; Chao-Kai Chou; Yi Du; Debanjan Dhar; Michael Karin; Chung-Hsuan Chen; Mien-Chie Hung
Journal:  Mol Cell       Date:  2011-12-22       Impact factor: 17.970

Review 3.  Glucocorticoid use in acute lymphoblastic leukaemia.

Authors:  Hiroto Inaba; Ching-Hon Pui
Journal:  Lancet Oncol       Date:  2010-10-12       Impact factor: 41.316

4.  MAGEA1 interacts with FBXW7 and regulates ubiquitin ligase-mediated turnover of NICD1 in breast and ovarian cancer cells.

Authors:  J Zhao; Y Wang; C Mu; Y Xu; J Sang
Journal:  Oncogene       Date:  2017-05-01       Impact factor: 9.867

5.  Cutting off the power: inhibition of leukemia cell growth by pausing basal ATP release and P2X receptor signaling?

Authors:  Carola Ledderose; Tobias Woehrle; Stephan Ledderose; Katharina Strasser; Richard Seist; Yi Bao; Jingping Zhang; Wolfgang G Junger
Journal:  Purinergic Signal       Date:  2016-03-28       Impact factor: 3.765

Review 6.  B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies.

Authors:  José P Vaqué; Nerea Martínez; Ana Batlle-López; Cristina Pérez; Santiago Montes-Moreno; Margarita Sánchez-Beato; Miguel A Piris
Journal:  Haematologica       Date:  2014-02       Impact factor: 9.941

7.  GSI-I (Z-LLNle-CHO) inhibits γ-secretase and the proteosome to trigger cell death in precursor-B acute lymphoblastic leukemia.

Authors:  X Meng; K Matlawska-Wasowska; F Girodon; T Mazel; C L Willman; S Atlas; I-M Chen; R C Harvey; S P Hunger; S A Ness; S S Winter; B S Wilson
Journal:  Leukemia       Date:  2011-04-15       Impact factor: 11.528

8.  The MEK/ERK pathway promotes NOTCH signalling in pancreatic cancer cells.

Authors:  Isabelle Tremblay; Emanuel Paré; Dominique Arsenault; Mélanie Douziech; Marie-Josée Boucher
Journal:  PLoS One       Date:  2013-12-31       Impact factor: 3.240

9.  Whole-exome sequencing in splenic marginal zone lymphoma reveals mutations in genes involved in marginal zone differentiation.

Authors:  N Martínez; C Almaraz; J P Vaqué; I Varela; S Derdak; S Beltran; M Mollejo; Y Campos-Martin; L Agueda; A Rinaldi; I Kwee; M Gut; J Blanc; D Oscier; J C Strefford; J Martinez-Lopez; A Salar; F Sole; J L Rodriguez-Peralto; C Diez-Tascón; J F García; M Fraga; E Sebastián; J Alvés; J Menárguez; J González-Carreró; L F Casado; M Bayes; F Bertoni; I Gut; M A Piris
Journal:  Leukemia       Date:  2013-12-03       Impact factor: 11.528

10.  KRT19 directly interacts with β-catenin/RAC1 complex to regulate NUMB-dependent NOTCH signaling pathway and breast cancer properties.

Authors:  S K Saha; H Y Choi; B W Kim; A A Dayem; G-M Yang; K S Kim; Y F Yin; S-G Cho
Journal:  Oncogene       Date:  2016-06-27       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.